TABLE 1

Treatment schedules for T. cruzi-infected mice with lychnopholide and control formulations during the acute phase of infection

Expt no. (treatment scheme) and T. cruzi strainDrug/formulationaTreatment period (days)Dose (mg/kg/day), i.v.b
Ic (24 h after infection), CL strain (sensitive to BZ)LYC-PCL NC
Free LYC102.0
BZ1050.0
Unloaded NC102.0*
DMA-PEG 300 (control i.v. solution)1050.0*
Untreated control
II (prepatent period, 7th day), CL strain (sensitive to BZ)LYC-PCL NC202.0
LYC-PLA-PEG NC202.0
Free LYC202.0
BZ2050.0
Unloaded NC202.0*
DMA-PEG 300 (control i.v. solution)2050.0*
Untreated control
III (24 h after infection), Y strain (partially resistant to BZ)LYC-PCL NC102.0
Free LYC102.0
BZ1050.0
Unloaded NC102.0*
DMA-PEG 300 (control i.v. solution)1050.0*
Untreated control2.0
IV (prepatent period, 4th day), Y strain (partially resistant to BZ)LYC-PCL NC202.0
LYC-PLA-PEG NC202.0
BZ2050.0
Unloaded NC202.0*
DMA-PEG 300 (control i.v. solution)2050.0*
Untreated control
  • a NC, nanocapsules.

  • b *, the amount of excipients used in DMA-PEG solution and in unloaded NC was the same as that used in BZ and LYC NC formulations.

  • c Infection was confirmed by hemoculture in all animals.